文献速递糖尿病肥胖与代谢综合征

早期时间限制性碳水化合物摄入与常规饮食在2型糖尿病中的比较:一项随机对照试验

Early time-restricted carbohydrate consumption vs conventional dieting in type 2 diabetes: a randomised controlled trial.
PubMed 文献 · Diabetologia · 2023-11-16

该随机对照试验在超重或肥胖的2型糖尿病患者中比较了12周早期时间限制性碳水化合物摄入(eTRC)与能量限制匹配的地中海风格对照饮食,主要结局为12周时HbA1c的组间差异。结果显示两组HbA1c、空腹血糖、血糖变异性及混合餐耐量试验衍生的血糖耐受、胰岛素抵抗、胰岛素清除率和血浆胰高血糖素水平均获得可比改善,eTRC未带来额外代谢获益。作者认为eTRC是血糖和体重管理的可行有效替代选择。

要点

  • 12周eTRC与对照饮食均降低HbA1c,组间差异无统计学意义(p=0.386)。
  • 两组体重和脂肪量降低程度相似,eTRC未显示额外代谢获益。
  • 探索性分析中,体重和糖代谢指标变化与碳水化合物摄入时间无关。

核心结论

  • eTRC饮食为2型糖尿病患者的血糖和体重管理提供了可行且有效的替代选择,但与常规饮食相比无额外代谢获益。

研究设计与样本

  • 随机、平行臂、开放标签、对照试验,纳入超重或肥胖的2型糖尿病患者(年龄67.2±7.9岁,女性47.8%,BMI 29.4±3.7 kg/m2,HbA1c 49±5 mmol/mol [6.6±0.5%]),随机分配至12周eTRC饮食或能量限制和宏量营养素分布匹配的地中海风格对照饮食(50%碳水化合物、30%脂肪、20%蛋白质)。
  • 主要结局为12周时HbA1c的组间差异;每4周进行体成分、14天瞬感血糖监测和食物日记分析;基线和12周后进行混合餐耐量试验及数学β细胞功能建模。

主要发现

  • eTRC组12例(85.7%)和对照组11例(84.6%)完成研究,两组体重和脂肪量降低相似。
  • 两组HbA1c改善可比:eTRC组-3 [-6, -0.3] mmol/mol vs 对照组-4 [-6, -2] mmol/mol(分别对应-0.2 [-0.5, 0]%和-0.3 [-0.5, -0.1]%),p=0.386。
  • 两组空腹血糖、瞬感血糖监测衍生的血糖变异性、混合餐耐量试验衍生的血糖耐受、胰岛素抵抗、胰岛素清除率和血浆胰高血糖素水平均获可比改善,模型衍生的β细胞功能参数、胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和非酯化脂肪酸水平无变化。
  • 两种饮食均相似降低肝功能标志物和甘油三酯水平,对其他心脏代谢和安全性变量呈中性。
  • 探索性分析中,饮食诱导的体重和糖代谢变量变化与碳水化合物摄入时间无关。

临床怎么用

  • 原文结论认为eTRC饮食为2型糖尿病患者的血糖和体重管理提供了可行且有效的替代选择,但与常规饮食相比无额外代谢获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Early time-restricted carbohydrate consumption (eTRC) is a novel dietary strategy that involves restricting carbohydrate-rich food intake to the morning and early afternoon to align with circadian variations in glucose tolerance. We examined the efficacy, feasibility and safety of eTRC in individuals with type 2 diabetes under free-living conditions. METHODS: In this randomised, parallel-arm, open label, controlled trial, participants with type 2 diabetes and overweight/obesity (age 67.2±7.9 years, 47.8% women, BMI 29.4±3.7 kg/m2, HbA1c 49±5 mmol/mol [6.6±0.5%]) were randomised, using computer-generated random numbers, to a 12 week eTRC diet or a Mediterranean-style control diet with matched energy restriction and macronutrient distribution (50% carbohydrate, 30% fat and 20% protein). The primary outcome was the between-group difference in HbA1c at 12 weeks. Body composition, 14 day flash glucose monitoring and food diary analysis were performed every 4 weeks. Mixed meal tolerance tests with mathematical beta cell function modelling were performed at baseline and after 12 weeks. RESULTS: Twelve (85.7%) participants in the eTRC arm and 11 (84.6%) participants in the control arm completed the study, achieving similar reductions in body weight and fat mass. The two groups experienced comparable improvements in HbA1c (-3 [-6, -0.3] mmol/mol vs -4 [-6, -2] mmol/mol, corresponding to -0.2 [-0.5, 0]% and -0.3 [-0.5, -0.1]%, respectively, p=0.386), fasting plasma glucose, flash glucose monitoring-derived glucose variability and mixed meal tolerance test-derived glucose tolerance, insulin resistance, insulin clearance and plasma glucagon levels, without changes in model-derived beta cell function parameters, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and non-esterified fatty acid levels. The two diets similarly reduced liver function markers and triglyceride levels, being neutral on other cardiometabolic and safety variables. In exploratory analyses, diet-induced changes in body weight and glucometabolic variables were not related to the timing of carbohydrate intake. CONCLUSIONS/INTERPRETATION: The proposed eTRC diet provides a feasible and effective alternative option for glucose and body weight management in individuals with type 2 diabetes, with no additional metabolic benefits compared with conventional dieting. TRIAL REGISTRATION: ClinicalTrials.gov NCT05713058 FUNDING: This study was supported by the European Society for Clinical Nutrition and Metabolism (ESPEN) and the Italian Society of Diabetology (SID).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Tricò D, Masoni MC, Baldi S, et al. Early time-restricted carbohydrate consumption vs conventional dieting in type 2 diabetes: a randomised controlled trial. Diabetologia. 2023. PMID: 37971503. doi:10.1007/s00125-023-06045-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。